ReviewApplied health economics and health policy2022
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.
Review in Applied health economics and health policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Comparison of Alternative Outcome Measures in Cost-Effectiveness Analysis: Three Applications Within Oncology.PharmacoEconomics · 2026Article
- Uncertainty in Economic Evaluation: A Pragmatic Guide for Health Technology Assessment (HTA) Agencies in Resource-Constrained Settings.PharmacoEconomics · 2026Review
- Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list system.Cost effectiveness and resource allocation : C/E · 2026Review
- The inaugural HEMA report: a missed opportunity for comprehensive value assessment.Journal of comparative effectiveness research · 2026Article
- Protocol for a Pre-Post Field Trial of a Home Hearing and Vision Care Program for Older Australians With Diverse Cognitive Abilities and Hearing and/or Vision Impairment.Health science reports · 2026Article
- Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.Nature reviews. Nephrology · 2025Review
- Return on investment of rapid ICU workforce upskilling: an economic and cost-effectiveness analysis.Intensive care medicine · 2025Article
- Exploring graphical approaches to assess the impact of an additional trial on a decision model via updated meta-analysis.Research synthesis methods · 2025Article
- Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.BMJ global health · 2024Article
- Resource allocation in public sector programmes: does the value of a life differ between governmental departments?Cost effectiveness and resource allocation : C/E · 2023Article
- Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.EClinicalMedicine · 2023Article
- A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany.Applied health economics and health policy · 2023Article
- How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition's Lung Facts.Applied health economics and health policy · 2023Article
- The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.PharmacoEconomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is growing interest in cost-effectiveness thresholds as a tool to inform resource allocation decisions in health care. Studies from several countries have sought to estimate health system opportunity costs, which supply-side cost-effectiveness thresholds are intended to represent. In this paper, we consider the role of empirical estimates of supply-side thresholds in policy-making. Recent studies estimate the cost per unit of health based on average displacement or outcome elasticity. We distinguish the types of point estimates reported in empirical work, including marginal productivity, average displacement, and outcome elasticity. Using this classification, we summarise the limitations of current approaches to threshold estimation in terms of theory, methods, and data. We highlight the questions that arise from alternative interpretations of thresholds and provide recommendations to policymakers seeking to use a supply-side threshold where the evidence base is emerging or incomplete. We recommend that: (1) policymakers must clearly define the scope of the application of a threshold, and the theoretical basis for empirical estimates should be consistent with that scope; (2) a process for the assessment of new evidence and for determining changes in the threshold to be applied in policy-making should be created; (3) decision-making processes should retain flexibility in the application of a threshold; and (4) policymakers should provide support for decision-makers relating to the use of thresholds and the implementation of decisions stemming from their application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.